Funded Startups in Wellesley
The disclosed funding amounts in Wellesley’s most recent entries cluster under $40M, but one outlier breaks the pattern: Talaris Therapeutics’ $115M round…
The disclosed funding amounts in Wellesley’s most recent entries cluster under $40M, but one outlier breaks the pattern: Talaris Therapeutics’ $115M round (2020-10-06) is far above the next-largest disclosed amount, Truvideo’s $40M (2024-12-10). That same set shows a dense late-period cluster: 6 of the 8 listed rounds fall between 2024-10-10 and 2025-02-04, with multiple checkpoints in December 2024 (Scripta Insights at $17M on 2024-12-18, Truvideo at $40M on 2024-12-10, and Allurion Technologies at $3M on 2025-01-14). Sector-wise, Biotechnology appears twice (Auron Therapeutics, 2025-02-04; Talaris Therapeutics, 2020-10-06) and Health Care appears three times (Allurion Technologies on 2025-01-14, Scripta Insights on 2024-12-18, and RevOps Health on 2024-10-10 is categorized as Data and Analytics). Stage reporting is incomplete: 2 of 8 rows are labeled “Series Unknown,” and 1 of 8 is “undisclosed,” spanning the same geography (Wellesley, MA) across the full date range from 2020-10-06 to 2026-06-29.
Most recent rounds
8 shownRelated listings
Frequently asked
What does the funding range look like, and is there a clear outlier in Wellesley?
Talaris Therapeutics’ $115M (2020-10-06) is an outlier, dwarfing the next-largest disclosed round at $40M from Truvideo (2024-12-10). The remaining disclosed amounts sit below $30M, including Nebex at $30M (2026-06-29) and Auron Therapeutics at $27M (2025-02-04).
Do the rounds cluster in a narrow time window among the most recent entries?
Yes. Of the 8 rows, 6 rounds date from 2024-10-10 through 2025-02-04, with two separate December 2024 entries at the $17M (Scripta Insights, 2024-12-18) and $40M (Truvideo, 2024-12-10) marks. The oldest row remains Talaris Therapeutics on 2020-10-06.
How concentrated are sectors in this Wellesley list?
Health Care spans three entries: Allurion Technologies ($3M, 2025-01-14), Scripta Insights ($17M, 2024-12-18), and RevOps Health is categorized under Data and Analytics (2024-10-10), so Health Care itself is concentrated in two named companies. Biotechnology appears in two rows (Auron Therapeutics at $27M on 2025-02-04 and Talaris Therapeutics at $115M on 2020-10-06).
Which stage classifications dominate, and how much is missing?
In this set of 8 rows, “Series Unknown” appears 2 times (Vanguard Renewables, undisclosed amount on 2025-08-20; Truvideo on 2024-12-10), while one row is explicitly “undisclosed” (Vanguard Renewables, 2025-08-20). Two rows are labeled “Series B” (Auron Therapeutics $27M on 2025-02-04; Scripta Insights $17M on 2024-12-18).
Which entries closed most recently, and how do the latest amounts compare to the mid-window rounds?
The most recent date is 2026-06-29 for Nebex with a disclosed $30M. In contrast, the mid-window late-2024/early-2025 rounds include RevOps Health at $2M (2024-10-10), Scripta Insights at $17M (2024-12-18), and Auron Therapeutics at $27M (2025-02-04).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.